Confirmed six-month disability progression rates over 4 years were similar in patients given the oral statin or a placebo in ...
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...
[5] Pinke KH, et al. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Neurotherapeutics. 2020 Jan;17(1):218-234. [6] Brown MA, Weinberg RB. Mast Cells and ...
Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
New research highlights the benefits of starting monoclonal antibody therapy for multiple sclerosis in childhood. The study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback